Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
PaperCitations, authors & open-access status
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 326 citations, 2018 year and closed oa status.
326
Citations
2018
Year
closed
OA Status